Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may forecast deadly pancreatic surgery complications

NCT ID NCT07144917

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

100 patients undergoing a Pancreaticoduodenectomy in one of the four participating centers for a benign or malignant tumor of the pancreatic head will be included. Participating centers : Hospices Civils de Lyon (Edouard Herriot Hospital, Croix-Rousse Hospital, Lyon Sud Hospital) and Centre Léon Bérard, Lyon, France

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any patient undergoing a Pancreaticoduodenectomy in one of the four participating centers for a benign or malignant tumor of the pancreatic head Exclusion Criteria: * Age \< 18 years * Pregnant, postpartum, or breastfeeding women * Indication other than tumor-related (e.g., chronic pancreatitis) * Patient with an infectious syndrome at the time of inclusion * Preoperative immunosuppression * Immunosuppressive disease other than cancer: * Congenital or acquired immune deficiency * Functional hyposplenism or asplenia, patient under long-term antibiotic prophylaxis for this reason * Patient with HIV (and CD4 \< cells/mm³) * Aplasia defined by circulating neutrophil count \< 500 cells/mm³ * Immunosuppressive treatment other than chemotherapy : Biotherapy, Corticosteroid therapy \>10 mg/day or cumulative dose \>700 mg prednisolone equivalent : Patient expected to receive immunosuppressive treatment within the first 7 postoperative days * Individuals deprived of liberty by judicial or administrative decisio * Adults under legal protection (guardianship or curatorship) * Individuals not affiliated with a social security scheme or an equivalent coverage * Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma (mpdac) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma Pancreatic Fistula pancreatic neoplasm Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic ductal adenocarcinoma (mpdac) Pancreatic fistula Pancreatic head tumour

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aurélien DUPRE

    NOT_YET_RECRUITING

    Lyon, 69008, France

  • Jean-Christophe LIFANTE

    NOT_YET_RECRUITING

    Pierre-Bénite, 69495, France

  • Julie PERINEL

    NOT_YET_RECRUITING

    Lyon, 69003, France

  • Xavier MULLER

    RECRUITING

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.